In a report released today, Liana Moussatos from Wedbush reiterated a Hold rating on Omeros Corp (OMER), with a price target of $18. The company’s shares closed on Friday at $15.70.
According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -8.9% and a 31.8% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Aquestive Therapeutics Inc, and Allena Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Omeros Corp with a $27.75 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $27 and a one-year low of $10.30. Currently, Omeros Corp has an average volume of 404.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
